HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic ?d T-cell Lymphoma

被引：2

作者：

Xu, Xueer ^{[1
,2
,3
,4
]}

Zu, Cheng ^{[1
,2
,3
,4
]}

Zhang, Mingming ^{[1
,2
,3
,4
]}

Xiao, Pingnan ^{[1
,2
,3
,4
]}

Hong, Ruimin ^{[1
,2
,3
,4
]}

Feng, Jingjing ^{[1
,2
,3
,4
]}

Xu, Huijun ^{[1
,2
,3
,4
]}

Cui, Jiazhen ^{[1
,2
,3
,4
]}

Yu, Jian ^{[1
,2
,3
,4
]}

Shi, Jimin ^{[1
,2
,3
,4
]}

Wei, Guoqing ^{[1
,2
,3
,4
]}

Chang, Alex H. ^{[5
,6
]}

Huang, He ^{[1
,2
,3
,4
]}

Hu, Yongxian ^{[1
,2
,3
,4
]}

机构：

[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, 79 Qingchun Rd, Hangzhou 310003, Peoples R China

[2] Zhejiang Univ, Med Ctr, Liangzhu Lab, Hangzhou, Peoples R China

[3] Zhejiang Univ, Inst Hematol, Hangzhou, Peoples R China

[4] Zhejiang Prov Engn Lab Stem Cell & Immun Therapy, Hangzhou, Peoples R China

[5] Shanghai Yake Biotechnol Ltd, Shanghai, Peoples R China

[6] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Clin Translat Res Ctr, 1600 Guo Quan Bei Lu,Build A8,Rm 204, Shanghai 200438, Peoples R China

来源：

CELL TRANSPLANTATION | 2023年 / 32卷

关键词：

immunology; T-lymphocytes; 1ST-IN-HUMAN;

D O I：

10.1177/09636897231194265

中图分类号：

Q813 [细胞工程];

学科分类号：

摘要：

While chimeric antigen receptor (CAR)-T-cell therapy has demonstrated remarkable effectiveness in the treatment of B-cell lymphomas and leukemias, research on T-cell malignancies is still limited. Here, we reported a patient with hepatosplenic & gamma;& delta; T-cell lymphoma refractory to multiple lines of chemotherapy, who eventually achieved first complete remission with flow cytometry-confirmed minimal residual disease negativity after human leukocyte antigen (HLA) fully-mismatched sibling-derived CD7 CAR-T therapy. However, given the allogeneic nature, CAR-T cells dropped rapidly after a peak of 83.4% of circulating T-cells. Cytokine release syndrome, cytopenia, and infections occurred but were manageable after treatments. After the consolidative haploidentical hematopoietic stem cell transplantation (HSCT), the patient remained in remission at the end of the follow-up (13 months post-CAR-T infusion). This is the first case of relapsed/refractory hepatosplenic & gamma;& delta; T-cell lymphoma who achieved lasting CR after HLA fully-mismatched sibling-derived CD7 CAR-T therapy bridging to haploidentical HSCT.

引用

页数：7